JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
New affiliate program and broader coin support launched as investor interest and regulatory clarity grow. Image by JAMining LONDON, May…
Double Deposit Bonus, $50 Welcome Bonus & No-KYC 100x Leverage Trading Now Available on BexBack
SINGAPORE, May 31, 2025 (GLOBE NEWSWIRE) — As the price of Bitcoin surpassed the $100,000 mark and subsequently stabilized above…
Direct Energy Regulated Services Announces Natural Gas Rates for June 2025
CALGARY, Alberta, May 31, 2025 (GLOBE NEWSWIRE) — Direct Energy Regulated Services has announced default natural gas rates for June…
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
Cloud mining platform offers low-barrier entry for retail investors with free $150 sign-up bonus Image by PAIRMiner STUTTGART, Germany, May…
Crypto Bubbles Come and Go: How Bitcoin Solaris’s Technology Aims for Stable, Long-Term Appreciation
TALLINN, Estonia, May 31, 2025 (GLOBE NEWSWIRE) — As Phase 5 of its limited presale nears completion, Bitcoin Solaris (BTC-S)…
Dignity Made Launches to Fight Trafficking with Ethical Coconut Oil
St. Paul, MN, May 31, 2025 (GLOBE NEWSWIRE) — Dignity Coconuts, known for its premium, ethically sourced coconut oil, has…
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)…
Maryland Student Wins NFTE Capital Youth Entrepreneurship Challenge
Students win $3,000 in Shark Tank-style pitch competition and advance to national finals NFTE Capital Youth Entrepreneurship Challenge Champion Arlo…
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic…
↑